Compare Cytokinetics Inc (CYTK) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Cytokinetics Inc trades at $62.77 (market cap $8.62B), while iShares Core MSCI Emerging Markets ETF trades at $81.29 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 18.8× Cytokinetics Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| CYTK | IEMG | |
|---|---|---|
Market Cap | $8.62B | $162.00B |
Volume | 2,594,626 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $86.00 |
52-Week Low | $54.76 | $64.22 |
Typical Hold Time | 19 Days | 57 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
IEMG trades at $81.29, down 0.91% with bearish technical signals dominating. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers and its appeal for long-term portfolio strategies despite higher volatility compared to developed market alternatives.
The outlook remains cautious given technical weakness, though emerging market exposure offers growth potential. Key risks include sector concentration in technology and emerging market volatility. Analyst comparisons favor IEMG for cost efficiency and performance, but investors should weigh higher drawdowns against return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
